Skip to main content

Table 5 Fatigue and quality of life of the study groups at baseline and week 12a

From: Effects of whole-body electromyostimulation combined with individualized nutritional support on body composition in patients with advanced cancer: a controlled pilot trial

Outcome Measure

Study group

n

Baseline

Week 12

Difference week 12

p b/c

p d

FACIT-Fatigue Scale

Control

18

33.11 ± 11.49

39.61 ± 7.69

6.50 ± 10.01

0.014 c

0.077

WB-EMS

52

36.81 ± 10.76

38.58 ± 9.74

1.77 ± 8.62

0.058b

EORTC QLQ-C30 Functional Scales

 Physical functioning

Control

19

74.37 ± 20.81

77.32 ± 15.51

2.95 ± 16.54

0.623b

0.542

WB-EMS

55

78.55 ± 20.12

80.47 ± 20.90

1.93 ± 17.11

0.276b

 Role functioning

Control

17

54.94 ± 27.56

66.65 ± 22.86

11.71 ± 31.79

0.149c

0.242

WB-EMS

55

63.62 ± 28.89

62.18 ± 30.15

− 1.44 ± 24.29

0.863b

 Emotional functioning

Control

19

63.53 ± 25.57

63.53 ± 25.86

0.00 ± 23.69

0.850b

0.096

WB-EMS

53

66.62 ± 21.26

73.06 ± 21.41

6.43 ± 16.82

0.007 c

 Cognitive functioning

Control

19

80.63 ± 21.71

85.05 ± 19.95

4.42 ± 20.69

0.265b

0.791

WB-EMS

53

78.00 ± 22.27

79.19 ± 24.01

1.19 ± 18.46

0.739b

 Social functioning

Control

19

50.89 ± 30.24

61.37 ± 28.88

10.47 ± 27.96

0.096b

0.501

WB-EMS

53

58.89 ± 28.80

65.42 ± 28.42

6.53 ± 22.88

0.054b

EORTC QLQ-C30 Symptom Scales

 Pain

Control

19

37.68 ± 30.81

16.58 ± 25.39

−21.11 ± 34.48

0.016 c

0.072

WB-EMS

54

25.24 ± 26.41

21.89 ± 28.87

− 3.35 ± 26.34

0.254b

 Dyspnea

Control

18

27.78 ± 32.92

22.11 ± 27.98

−5.67 ± 26.20

0.196b

0.166

WB-EMS

55

22.95 ± 27.13

27.82 ± 31.31

4.87 ± 25.98

0.156b

 Insomnia

Control

18

36.89 ± 30.07

29.61 ± 32.19

−7.28 ± 37.21

0.418c

0.606

WB-EMS

55

28.45 ± 32.40

25.38 ± 29.40

−3.07 ± 35.39

0.379b

 Appetite loss

Control

18

40.72 ± 37.22

24.06 ± 32.00

− 16.67 ± 46.45

0.193b

0.051

WB-EMS

55

21.20 ± 31.06

15.72 ± 28.59

−5.47 ± 27.81

0.119b

 Constipation

Control

19

22.84 ± 33.52

19.26 ± 30.08

−3.58 ± 35.12

0.619b

0.522

WB-EMS

53

16.32 ± 28.97

14.40 ± 24.87

−1.92 ± 30.94

0.617b

 Diarrhea

Control

18

25.94 ± 29.39

25.94 ± 33.53

0.00 ± 25.70

1.000b

0.563

WB-EMS

53

21.32 ± 27.87

17.58 ± 25.03

−3.74 ± 28.25

0.591b

 Financial difficulties

Control

19

22.79 ± 31.58

33.32 ± 38.54

10.53 ± 29.42

0.107b

0.206

WB-EMS

52

21.79 ± 27.21

21.12 ± 28.83

− 0.67 ± 29.87

0.711b

 Nausea/Vomiting

Control

18

21.39 ± 24.06

15.72 ± 25.17

− 5.67 ± 37.00

0.524c

0.752

WB-EMS

55

12.72 ± 17.17

6.69 ± 13.06

−6.04 ± 18.19

0.032 b

 Fatigue

Control

18

51.17 ± 22.49

33.89 ± 22.87

−17.28 ± 28.58

0.020 c

0.135

WB-EMS

55

43.05 ± 28.23

39.96 ± 27.89

−3.09 ± 25.01

0.185b

 Global Health

Control

18

54.17 ± 19.52

66.67 ± 20.20

12.50 ± 24.77

0.047 c

0.157

WB-EMS

53

59.40 ± 18.19

61.49 ± 20.78

2.09 ± 19.63

0.247b

  1. Statistically significant differences are marked in bold type and indicated by p < 0.05
  2. Abbreviations: WB-EMS Whole-body electromyostimulation
  3. aIncludes patients with both baseline and post-test data. Data are presented as mean ± SD
  4. bComparison of intragroup differences in baseline and post-intervention data (Wilcoxon signed-rank test)
  5. cComparison of intragroup differences in baseline to 12-week post-intervention changes (paired samples t-test)
  6. dComparison of differences in baseline to 12-week post-intervention changes between the groups (Mann-Whitney-U-test)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us